Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...

Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...